Gavi: Vaccine Patches Could Transform Immunisation Coverage in Lower-Income Countries
Micro Array Patches (MAPs) present a potentially transformative solution for vaccine delivery in LMIC's, addressing numerous challenges faced by traditional intradermal methods and maximizing vaccination reach. Benefits include simplifying administration by minimally trained volunteers, enhancing safety by eliminating operational errors and needle-stick injuries, and facilitating distribution due to their shape and lightweight nature. Moreover, MAPs boast enhanced thermostability, reducing reliance on cold chains, and are cost-effective, with reduced pain during administration aiding vaccine acceptance.
Despite their promise, no MAPs have been approved by regulators yet, though clinical trials, particularly for measles-rubella vaccines, have shown promising results. Studies in LMICs have demonstrated the acceptability and usability of MAPs among healthcare workers and communities, though challenges such as logistical concerns and production scalability remain. Collaboration and investment are crucial to advancing MAPs technology and integrating it into routine immunization programs globally, offering a promising avenue for expanding vaccine coverage and improving public health outcomes. To read more about MAPs, current trials taking place, and Gavi's hopes for this transformative solution to be used in the future, click the link below!